Therapeutic value of quinazoline-based compounds in prostate cancer

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4695-4700

  Bilbro, Johnathan ^a   Mart, Matthew ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Anoikis; Doxazosin; DZ 50; Prostate cancer; Quinazoline; Review; Terazosin; Vascularity

Indexed keywords

ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CASTRATION RESISTANT PROSTATE CANCER; CELL INTERACTION; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; REVIEW;

ANOIKIS; DOXAZOSIN; DZ-50; PROSTATE CANCER; QUINAZOLINE; REVIEW; TERAZOSIN; VASCULARITY;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUINAZOLINES;

EID: 84891369678     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Altekruse SF et al: SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
2. Garrison JB and Kyprianou N: Novel targeting of apoptosis pathways for prostate cancer therapy. Curr Cancer Drug Targets 4(1): 85-95, 2004.
3. Kibel AS: An interdisciplinary approach to treating prostate cancer. Urology 65(6): 13-18, 2005.
4. Daneshgari F and Crawford ED: Endocrine therapy of advanced carcinoma of the prostate. Cancer 71: 1089-1097, 1993.
5. Arnold JT and Isaacs JT: Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer 9(1): 61-73, 2002.
6. Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351(15): 1488-90, 2004.
7. McKenzie S and Kyprianou N: Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem 97(1): 18-32, 2006.
8. Dameron KM, Volpert OV, Tainsky MA and Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265(5178): 1582-1584, 1994.
9. Borre M, Offersen BV, Nerstrom B and Overgaard J: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78(7): 940-944, 1998.
10. Albertsen PC, Fryback DG, Storer BE, Kolon TF and Fine J: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274(8): 626-631, 1995.
11. Tahmatzopoulos A, Rowland RG, Kyprianou N: The role of α- blockers in the management of prostate cancer. Expert Opin Pharmacother 5(6): 1279-1285, 2004
12. Sakamoto S, Ryan AJ and Kyprianou N: Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance. J Cell Biochem 103(3): 691-708, 2008.
13. Keledjian K et al: Reduction of human prostate tumor vascularity by the α1-adrenoceptor antagonist terazosin. Prostate 48(2): 71-78, 2001.
14. Pan SL et al: Identification of apoptotic and anti-angiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 169(2): 724-729, 2003.
15. Keledjian K, Garrison JB and Kyprianou N: Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 94(2): 374-388, 2005.
16. Kyprianou N and Benning CM: Suppression of human prostate cancer cell growth by alpha1-adrenoreceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60(16): 4550-4555, 2000.
17. Kyprianou N, Litvak JP, Borkowski A, Alexander R and Jacobs SC: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159(6): 1810-1815, 1998.
18. Chon JK et al: Alpha-1 adrenoreceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161(6): 2002-2008, 1999.
19. Anglin IE, Glassman DT and Kyprianou N: Induction of prostate apoptosis by α1-adrenoreceptor antagonists: Mechanistic significance of the quinazoline component. Prost Cancer and Prost Dis 5: 88-95, 2002.
20. Shaw YJ, Yang YT, Garrison JB, Kyprianou N and Chen CS: Pharmacological exploitation of the α1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem 47(18): 4453-4462, 2004.
21. Garrison JB, Shaw YJ, Chen CS and Kyprianou N: Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res 67(23): 11344-11352, 2007.
22. Giardinà D et al: Doxazosin-related α1-adrenoceptor antagonists with prostate antitumor activity. J Med Chem 52(15): 4951-4954, 2009.
23. Forray C et al: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol 45(4): 703-708, 1994.
24. Benning CM and Kyprianou N: Quinazoline-derived alpha1-adrenoreceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoreceptor independent action. Cancer Res 62(2): 597-602, 2002.
25. Partin JV, Anglin IE and Kyprianou N: Quinazoline-based α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signaling and IκBα induction. Br J Canc 88(10): 1615-1621, 2003.
26. Baldwin AS: The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol 14: 649-681, 1996.
27. Sakamoto S, Schwarze S and Kyprianou N: Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur Urol 59(5): 734-744, 2011.
28. Garrison JB and Kyprianou N: Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptormediated pathway. Cancer Res 66(1): 464-472, 2006.
29. Barbero S et al: Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 69(9): 3755-3763, 2009.
30. Fornaro M, Manes T and Languino LR: Integrins and prostate cancer metastases. Cancer Metastasis Rev 20(3-4): 321-331, 2001.
31. Sakamoto S and Kyprianou N: Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med 31(2): 205-214, 2010.
32. Rovin JD, Frierson HF, Ledinh W, Parsons JT and Adams RB: Expression of focal adhesion kinase in normal and pathologic human prostate tissues. The Prostate 53(2): 124-132, 2002.
33. Goel HL, Alam N, Johnson INS and Languino LR: Integrin signaling aberrations in prostate cancer. Am J Transl Res 1(3): 211-220, 2009.
34. Fizazi K: The role of Src in prostate cancer. Ann Oncol 18(11): 1765-1773, 2007.
35. Desiniotis A and Kyprianou N: Significance of talin in cancer progression and metastasis. Int Rev Cell Mol Biol 289: 117-147, 2011.
36. Lee YC et al: Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res 11(4): 405-417, 2013.
37. Walden PD, Globina Y and Nieder A: Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. Urol Res 32(4): 261-265, 2004.
38. Shintani S, Li C, Mihara M, Nakashiro K and Hamakawa H: Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 201(2): 149-155, 2003.
39. Zhang S et al: SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 17(13): 4439-4450, 2011.
40. Kendrew J et al: Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemother Pharmacol 71(4): 1021-1032, 2013.
41. Chang KL et al: Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. Cancer Lett 276(1): 14-20, 2009.
42. Fukuoka M et al: Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21(12): 2237-2246, 2003.
43. Kris MG et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290(16): 2149-2158, 2003.
44. Tamura K et al: Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98(5): 907-914, 2008.
45. Cohen MH, Williams GA, Sridhara R, Chen G and Pazdur R: FDA drug approval summary: Gefitinib (ZD1839) (Iressa®) tablets. The Oncologist 8(4): 303-306, 2003.
46. Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6(12): 4885-4892, 2000.
47. Sirotnak FM, She Y, Lee F, Chen J and Scher HI: Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 8(12): 3870-3876, 2002.
48. Herbst RS et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20(18): 3815-3825, 2002.
49. Canil CM et al: randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23(3): 455-460, 2005.
50. Boccardo F et al: Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: A randomized phase II trial. Oncology 74(3-4): 223-228, 2008.
51. Gravis G et al: Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 19(9): 1624-1628, 2008.
52. Dahut WL et al: Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU International 111(8): 1269-1280, 2013.
53. Argiris A et al: Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 31(11): 1405-1414, 2013.
54. Gross M et al: A phase II trial of docetaxel and erlotinib as firstline therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7: 142-147, 2007.
55. Goss GD et al: Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 28(1): 49-55, 2010.
56. Harris AM et al: Effect of α1-adrenoreceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178(5): 2176-2180, 2007.
57. Jan Y et al: A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and groucho/TLE corepressors. Cell 116(5): 751-762, 2004.
58. Jenning S, Pham T, Ireland SK, Ruoslahti E and Biliran H: Bit1 in anoikis resistance and tumor metastasis. Cancer Lett 333(2): 147-151, 2013.
59. Simmons MN and Klein EA: Combined androgen blockade revisited: Emerging options for the treatment of castration-resistant prostate cancer. Urology 73(4): 697-705, 2009.
60. Thompson IM et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3): 215-224, 2003.
61. Murtola TJ, Kujala PM and Tammela TLJ: High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers. The Prostate 73(9): 923-931, 2013.
62. McConnell JD et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25): 2387-2398, 2003.